Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000654657 | SCV000776554 | pathogenic | Hyperkalemic periodic paralysis | 2024-04-22 | criteria provided, single submitter | clinical testing | This sequence change affects an acceptor splice site in intron 2 of the SCN4A gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in SCN4A are known to be pathogenic (PMID: 26700687). This variant is present in population databases (no rsID available, gnomAD 0.005%). Disruption of this splice site has been observed in individual(s) with clinical features of autosomal recessive SCN4A-related conditions (Invitae). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 543805). Experimental studies and prediction algorithms are not available or were not evaluated, and the effect of this variant on mRNA splicing is currently unknown. For these reasons, this variant has been classified as Pathogenic. |
Fulgent Genetics, |
RCV002477458 | SCV002785803 | uncertain significance | Hypokalemic periodic paralysis, type 1; Potassium-aggravated myotonia; Paramyotonia congenita of Von Eulenburg; Hypokalemic periodic paralysis, type 2; Hyperkalemic periodic paralysis; Congenital myasthenic syndrome 16 | 2021-09-22 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV003140044 | SCV003821269 | uncertain significance | not provided | 2022-01-11 | criteria provided, single submitter | clinical testing |